198630-93-2

Basic information

• Product Name: METHYL-2-BROMO-4-METHOXYPHENYLACETATE
• Synonyms: METHYL-2-BROMO-4-METHOXYPHENYLACETATE
• CAS NO: 198630-93-2
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.1
• Mol File: 198630-93-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL-2-BROMO-4-METHOXYPHENYLACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-2-BROMO-4-METHOXYPHENYLACETATE(198630-93-2)
• EPA Substance Registry System: METHYL-2-BROMO-4-METHOXYPHENYLACETATE(198630-93-2)

Safety Data

• Hazardous Substances Data: 198630-93-2(Hazardous Substances Data)

Usage

General Description

Methyl-2-bromo-4-methoxyphenylacetate is a chemical compound with the molecular formula C10H11BrO3. It is an ester, which means it is formed from the reaction of an alcohol and an organic acid. METHYL-2-BROMO-4-METHOXYPHENYLACETATE is commonly used in the synthesis of pharmaceuticals and other organic compounds, due to its versatile reactivity and its ability to act as a precursor to more complex molecules. It is also known for its mild, sweet, floral odor, which makes it a popular choice for use in perfumes and other fragrances. However, it is important to handle this chemical with care, as it is considered harmful if swallowed, inhaled, or in contact with skin, and may cause irritation to the respiratory system and skin.

Upstream product

• 67-56-1 methanol 
• 66916-99-2 2-(2-bromo-4-(methoxy)phenyl)acetic acid 
• 36942-56-0 3-bromo-4-methylanisole 
• 54788-18-0 2-bromo-1-(bromomethyl)-4-methoxybenzene 
• 66916-98-1 2-(2-bromo-4-methoxyphenyl)acetonitrile 

Downstream Products

• 1069114-97-1 methyl 2-(2-bromo-4-methoxylphenyl)-2-methylpropanoate 
• 1644247-57-3 methyl 2-acetoxy-2-(2-bromo-4-methoxyphenyl)acetate 
• 1644247-67-5 methyl 2-(2-bromo-4-methoxyphenyl)-2-(phenylthio)acetate 
• 1644247-45-9 methyl 2-(2-bromo-4-methoxyphenyl)-2-diazoacetate 
• 66916-99-2 2-(2-bromo-4-(methoxy)phenyl)acetic acid 
• 54300-95-7 7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-2H-chromen-2-one 
• 1690-62-6 3-hydroxy-9-methoxy-6H-benzofuro[3,2-c]chromen-6-one 
• 154352-91-7 methyl 2-bromo-4-hydroxyphenylacetate 
• 1334783-14-0 5-methoxy-2-(2-{2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}-2-oxoethyl)benzonitrile 
• 1454883-64-7 1-(2-bromo-4-methoxybenzyl)-6,7-dimethoxyisochroman 
• 1379317-71-1 2-(2-bromo-4-methoxyphenyl)acetaldehyde 
• 52786-67-1 (2-cyano-4-methoxyphenyl)acetic acid 
• 1261620-25-0 (2-bromo-4-methoxy-phenyl)-acetic acid 

Relevant articles and documents

Palladium-Catalyzed [4 + 3] or [2 + 2 + 3] Annulation via C-H Activation and Subsequent Decarboxylation: Access to Heptagon-Embedded Polycyclic Aromatic Hydrocarbons

The construction of a seven-membered ring in the polycyclic aromatic hydrocarbon skeleton remains a notoriously difficult but attractive challenge. Herein a novel palladium-catalyzed [4 + 3] decarboxylative annulation of 2-iodobiphenyls with 2-(2-halophenyl)acrylic acids is reported, which provides an efficient approach for assembling various tribenzo[7]annulenes via a C-H activation and decarboxylation process. Moreover, tribenzo[7]annulenes can be also synthesized via a [2 + 2 + 3] decarboxylative annulation strategy by employing readily available 1,2-halobenzenes, phenylboronic acids, and 2-(2-halophenyl)acrylic acids.

Internal Nucleophilic Catalyst Mediated Cyclisation/Ring Expansion Cascades for the Synthesis of Medium-Sized Lactones and Lactams

A strategy for the synthesis of medium-sized lactones and lactams from linear precursors is described in which an amine acts as an internal nucleophilic catalyst to facilitate a novel cyclisation/ring expansion cascade sequence. This method obviates the n

Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists

Several polar heteroaromatic acetic acids and their piperidine amides were synthesized and evaluated as ghrelin or type 1a growth hormone secretagogue receptor (GHS-R1a) inverse agonists. Efforts to improve pharmacokinetic and safety profile was achieved